GSK plc reports

Company location
London
GSK plc has filed 6,806 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 501-525 of 1,000 matching filings.

Per page
25
Current page
21
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
18 Mar 2025
Reporting date
18 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
17 Mar 2025
Reporting date
17 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
14 Mar 2025
Reporting date
14 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
14 Mar 2025
Reporting date
14 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
8-A12B File 001-15170

8-A12B

Filing date
13 Mar 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-A12B File 001-15170

8-A12B

Filing date
13 Mar 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

6-K

Filing date
13 Mar 2025
Reporting date
13 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
13 Mar 2025
Reporting date
13 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
12 Mar 2025
Reporting date
12 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
11 Mar 2025
Reporting date
11 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
10 Mar 2025
Reporting date
10 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-84251

SCHEDULE 13G/A filing

Filing date
07 Mar 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
07 Mar 2025
Reporting date
07 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
FWP File 333-278205

FWP

Filing date
07 Mar 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
424B2 File 333-278205

424B2

Filing date
06 Mar 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
06 Mar 2025
Reporting date
06 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
05 Mar 2025
Reporting date
05 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
04 Mar 2025
Reporting date
04 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK PLC 2024 ANNUAL REPORT ON FORM 20-F

Filing date
03 Mar 2025
Reporting date
03 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
IRANNOTICE File 001-15170

IRANNOTICE

Filing date
03 Mar 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
03 Mar 2025
Reporting date
03 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS

Filing date
03 Mar 2025
Reporting date
03 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

ANCHOR RESULTS PRESENTED AT 2025 AAAAI

Filing date
03 Mar 2025
Reporting date
03 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .